Transcat, Inc. (NASDAQ:TRNS) Shares Sold by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC lowered its position in Transcat, Inc. (NASDAQ:TRNS) by 6.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,909 shares of the scientific and technical instruments company’s stock after selling 389 shares during the period. Anchor Capital Advisors LLC owned approximately 0.07% of Transcat worth $646,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of TRNS. Comerica Bank purchased a new position in shares of Transcat during the 3rd quarter valued at about $5,221,000. Vanguard Group Inc. raised its position in Transcat by 13.3% during the third quarter. Vanguard Group Inc. now owns 425,378 shares of the scientific and technical instruments company’s stock valued at $41,674,000 after acquiring an additional 49,828 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Transcat by 196.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 59,482 shares of the scientific and technical instruments company’s stock valued at $5,827,000 after acquiring an additional 39,432 shares in the last quarter. Kornitzer Capital Management Inc. KS lifted its holdings in Transcat by 103.2% in the third quarter. Kornitzer Capital Management Inc. KS now owns 63,200 shares of the scientific and technical instruments company’s stock valued at $6,192,000 after acquiring an additional 32,100 shares during the period. Finally, EAM Investors LLC purchased a new stake in Transcat in the 3rd quarter worth approximately $2,962,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Transcat Stock Down 3.0 %

Shares of NASDAQ TRNS opened at $107.37 on Wednesday. Transcat, Inc. has a 52-week low of $76.05 and a 52-week high of $116.19. The company has a quick ratio of 2.81, a current ratio of 3.37 and a debt-to-equity ratio of 0.01. The company’s 50-day simple moving average is $108.77 and its 200-day simple moving average is $102.86. The firm has a market cap of $948.08 million, a price-to-earnings ratio of 82.59 and a beta of 0.59.

Transcat (NASDAQ:TRNS) last announced its earnings results on Monday, January 29th. The scientific and technical instruments company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.03. The business had revenue of $65.17 million during the quarter, compared to analysts’ expectations of $63.36 million. Transcat had a return on equity of 9.32% and a net margin of 4.16%. Equities analysts predict that Transcat, Inc. will post 1.34 EPS for the current fiscal year.

Insider Activity at Transcat

In other news, Director Charles P. Hadeed sold 700 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $113.00, for a total value of $79,100.00. Following the completion of the sale, the director now directly owns 22,678 shares in the company, valued at $2,562,614. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Charles P. Hadeed sold 700 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $113.00, for a total transaction of $79,100.00. Following the transaction, the director now directly owns 22,678 shares in the company, valued at approximately $2,562,614. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Lee D. Rudow sold 5,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $111.30, for a total value of $556,500.00. Following the completion of the sale, the chief executive officer now directly owns 108,478 shares of the company’s stock, valued at approximately $12,073,601.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,073 shares of company stock valued at $900,023. 4.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on TRNS shares. HC Wainwright reaffirmed a “buy” rating and set a $124.00 target price on shares of Transcat in a report on Tuesday, April 16th. Oppenheimer reissued an “outperform” rating and set a $125.00 target price (up from $120.00) on shares of Transcat in a research note on Thursday, April 18th. Finally, TheStreet upgraded Transcat from a “c+” rating to a “b” rating in a research note on Wednesday, January 31st.

About Transcat

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.